This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF▼ Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

TKIs in CML and the holistic approach to treatment decisions video

Speaker: Professor Richard Clark

Duration: 03:56

In this video, Richard discusses:

  • ​​​​​​​Chromosomal abnormalities
  • Prognostic markers
  • Longer term clinical data for bosutinib
  • His approach to changing treatments either due to efficacy or side effects

Richard Clark is Professor of Haematology at the University of Liverpool, UK. He studied medicine at Cambridge and Westminster Medical School, London, and, after his junior posts, co-established myeloid leukaemia research at Cardiff with Professor Allan Jacobs, as a research fellow and later Senior Lecturer. He moved to Liverpool in 1990 as Senior Lecturer and Consultant Haematologist and Director of the Regional Bone Marrow Transplant (BMT) programme at Royal Liverpool University Hospital. 
​​​​​​​Professor Clark’s research interests over the past 30 years have been in myeloid leukaemias, especially chronic myeloid leukaemia (CML). He is the chief or principal investigator for numerous trials in both acute leukaemia and myeloid malignancies and most recently the lead and chief investigator of one of the largest UK-wide study of discontinuation of TKIs in CML. 

Explore more

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Explore more

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video​​​​​​​​​​​​

Learn more
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
PP-BOS-GBR-1311. September 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No